Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (NYSE: LCTX) is a clinical-stage biotechnology company developing allogeneic cell replacement therapies for serious medical conditions. Its AlloSCOPE platform uses pluripotent cells to produce differentiated cells intended to replace or support cells lost or impaired through disease,… From the company’s description.
Over the twelve months to Jun 30, 2026, Lineage Cell Therapeutics, Inc. reported revenue of $13.08M, up 19.9% from a year earlier, and a net loss of $32.26M. Its operating margin was −205.2%, and operations used $23.82M in cash. In fiscal 2025, it reported revenue of $14.56M, up 53.2% from fiscal 2024, and a net loss of $63.53M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lineage Cell Therapeutics, Inc. does
In the company’s own words
Lineage Cell Therapeutics, Inc. (NYSE: LCTX) is a clinical-stage biotechnology company developing allogeneic cell replacement therapies for serious medical conditions. Its AlloSCOPE platform uses pluripotent cells to produce differentiated cells intended to replace or support cells lost or impaired through disease, aging or injury. Its pipeline includes OpRegen, a retinal pigment epithelial cell therapy for geographic atrophy secondary to dry age-related macular degeneration, developed with Roche and Genentech; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ReSonance, an auditory neuron progenitor cell therapy for hearing loss, developed with William Demant Invest 2; and earlier-stage research programs addressing potential treatments for Type 1 diabetes, vision loss and other indications. The company also develops manufacturing, formulation and delivery capabilities for its cell transplant candidates. Its product candidates are investigational, with OpRegen in Phase 2a development, OPC1 in Phase 1/2a development, and ReSonance in preclinical development. Lineage conducts cell banking and product manufacturing at its subsidiary’s facility in Jerusalem, Israel. Its website is https://lineagecell.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CARLSBAD, CA
- Fiscal year end
- December
- CIK
- 876343
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lineage Cell Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lineage Cell Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lineage Cell Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lineage Cell Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lineage Cell Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”